Johnson & Johnson COVID-19 vaccine produces strong results

▴ Johnson & Johnson COVID-19 vaccine produces strong results
The vaccine, called Ad26.COV2.S, was equally well-tolerated at two different doses, the results showed

A single dose of Johnson & Johnson's experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, according to interim results published on Friday.

The vaccine, called Ad26.COV2.S, was equally well-tolerated at two different doses, the results showed. A single shot, versus a rival two-dose approach being tested by Moderna Inc and Pfizer Inc, could simplify the distribution of the vaccine.

However, it is unclear whether elderly people, one of the populations most at risk from the virus, will be protected to the same degree as younger people with the J&J vaccine.

The trial in close to 1,000 healthy adults, which is backed by the U.S. government, began after the J&J vaccine was found in July to offer strong protection in a single dose to monkeys.

Based on the current results, J&J on Wednesday kicked off a final 60,000-person trial, which could pave the way for an application for regulatory approval. The company said it expects results of that so-called Phase 3 trial by the end of the year or early next year.

The results, released on the medical website medRxiv, have not been peer-reviewed. (https://bit.ly/2G3Ni1X)

Researchers, including those from J&J's unit Janssen Pharmaceuticals, said 98% of participants with data available for the interim analysis had neutralizing antibodies, which defend cells from pathogens, 29 days after vaccination.

However, immune response results were available from only a small number of people - 15 participants - over 65 years old, limiting the interpretation.

In participants older than 65, the rate of adverse reactions such as fatigue and muscle aches was 36%, much lower than the 64% seen in younger participants, the results showed, suggesting the immune response in older people may not be as strong.

The researchers said more details on safety and effectiveness will follow when the study is completed.

For now, the results justify why more studies are needed in larger numbers to look for serious adverse effects, Dr. Barry Bloom, a professor at Harvard T.H. Chan School of Public Health who was not involved in the J&J trial, told Reuters.

"Overall, the vaccine is doing what you would expect it to do if you were to move it to Phase 3 trials," Bloom said.

Tags : #JohnsonJohnson #COVID-19 #Result #Immunity

About the Author


Dr. Naila Syed

A well presented, self-motivated, and confident writer. Passionate about educating the masses on medical and nonmedical ways to promote health and lifestyle through my mighty pen.You can write to me at [email protected]

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

To stay well during festive seasonOctober 21, 2020
The fastest growing and the most awarded Cath Lab of India in 2018 is bringing affordable and accessible healthcare available for cardiovascular diseases in India saOctober 21, 2020
ViiV healthcare development program on cabotegravir and rilivirine has no pandemic interruptionsOctober 21, 2020
No significant clinical benefit with Umifenovir addition in COVID-19 treatment: Glenmark clinical study October 21, 2020
India sustains the continued trend of consistent decline in Active CasesOctober 21, 2020
Lifeness Science Institute by Luke Coutinho Introduces Programmes in Integrative Nutrition and DieteticsOctober 21, 2020
Lifeness Science Institute by Luke Coutinho Introduces Programmes in Integrative Nutrition and DieteticsOctober 21, 2020
Haryana tops Anemia Mukt Bharat Index in countryOctober 21, 2020
Covid Update: Assam & OdishaOctober 21, 2020
BriaCell announces the overall breast cancer survival (OS) data of its lead product candidate, Bria-IMT™October 21, 2020
Teladoc Health Data Shows Broadening Mental Health Care DemandOctober 21, 2020
China vaccinated 60,000 people: Result awaited October 21, 2020
Lilly hires outside advisor for COVID drug plant problemsOctober 21, 2020
No Child Mothers, Accelerating the reduction of adolescent pregnancies on occasion of Adolescent Pregnancy Prevention Week October 21, 2020
Tyber Medical receives US FDA clearance on foot and ankle plating systemsOctober 21, 2020
Green tea and coffee connected to lower death risk in people with diabetesOctober 21, 2020
MEDICAL FESTIVAL ASIA: Events for the region’s medical and healthcare sectorOctober 21, 2020
Selecta Biosciences and Asklepios BioPharmaceutical receives US FDA approval for their gene therapyOctober 21, 2020
Astellas Pharma received US FDA approval for the treatment of primary mitochondrial myopathiesOctober 21, 2020
GSK presents positive clinical data on maternal and older adults RSV candidate vaccinesOctober 21, 2020